|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:23,236,573...23,256,158
Ensembl chr 2:23,236,575...23,256,158
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:239,397,322...239,474,931
Ensembl chr 1:239,398,043...239,474,931
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:120,168,437...120,168,511
Ensembl chr 5:120,168,433...120,168,515
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:60,755,285...60,755,369
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:221,634,971...221,635,080
Ensembl chr 1:221,634,971...221,635,080
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:24,590,645...24,619,639
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:235,311,664...235,327,972
Ensembl chr 2:235,311,719...235,327,972
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:23,236,573...23,256,158
Ensembl chr 2:23,236,575...23,256,158
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:239,397,322...239,474,931
Ensembl chr 1:239,398,043...239,474,931
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:120,168,437...120,168,511
Ensembl chr 5:120,168,433...120,168,515
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:60,755,285...60,755,369
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:221,634,971...221,635,080
Ensembl chr 1:221,634,971...221,635,080
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:24,590,645...24,619,639
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:235,311,664...235,327,972
Ensembl chr 2:235,311,719...235,327,972
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:23,236,573...23,256,158
Ensembl chr 2:23,236,575...23,256,158
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:239,397,322...239,474,931
Ensembl chr 1:239,398,043...239,474,931
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:120,168,437...120,168,511
Ensembl chr 5:120,168,433...120,168,515
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:60,755,285...60,755,369
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:221,634,971...221,635,080
Ensembl chr 1:221,634,971...221,635,080
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:24,590,645...24,619,639
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:235,311,664...235,327,972
Ensembl chr 2:235,311,719...235,327,972
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein |
CTD |
PMID:10713328 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein |
CTD |
PMID:12824290 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednra |
endothelin receptor type A |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA |
CTD |
PMID:12824290 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
EXP |
1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA |
CTD |
PMID:12824290 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein] |
CTD |
PMID:25517228 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases activity decreases expression |
EXP ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein] 1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]] 1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein |
CTD |
PMID:12824290 PMID:19833176 PMID:25517228 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]] |
CTD |
PMID:25517228 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; [ALDH2 protein affects the abundance of Tetrahydropapaveroline] which affects the susceptibility to Cocaine; [CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline |
CTD |
PMID:20729865 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:8186192 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:8186192 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:8186192 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|